AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease August 13, 2025
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition August 12, 2025
Immunitas Therapeutics Presents Preclinical Data on IMT-380, a First-in-Class Anti-CD161 Antibody, at FASEB Science Research Conference on Autoimmunity July 31, 2025
AAVantgarde Bio: A 38-year-old man regains his sight thanks to an innovative gene therapy, a world first. July 30, 2025
KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks July 28, 2025
